Session Title: Uveitis & Intraocular Tumours
Session Date/Time: Friday 27/09/2013 | 14:30-16:00
Paper Time: 14:38
Venue: Hall C (Level 1)
First Author: K.Nakai JAPAN
Co Author(s): K. Nishida
To evaluate the long-term effect of infliximab (IFX) for treating Bechet's uveitis.
Retrospective review of 24 patients treated with IFX and followed 24 months (M).
The inflammation was scored 0-3 6 M before and every 6 M after IFX. Patients were divided in two groups (one with long-term efficacy and the other with lost response), based on the score. The C-reactive protein (CRP) level was measured.
Seven patients had a lost response (scores: 6.3 before IFX; 1.4, 0-6 M after IFX; 2.1, 6-12 M; 2.7 12-18 M). Seventeen patients had long-term efficacy (scores: 3.8, 0.3, 0.1 and 0.1, respectively); the scores was significantly lower (P<.05) even before IFX, with no significant difference in CRP.
Patients with high inflammation scores before IFX should be observed carefully.